Considerations in the choice of oral vs. transdermal hormone therapy: a review.

@article{Minkin2004ConsiderationsIT,
  title={Considerations in the choice of oral vs. transdermal hormone therapy: a review.},
  author={Mary Jane Minkin},
  journal={The Journal of reproductive medicine},
  year={2004},
  volume={49 4},
  pages={311-20}
}
The benefit/risk profile of postmenopausal hormone therapy has been under greater scrutiny since Women's Health Initiative study data were published in July 2002. A nominal analysis showed the study drug, a combination of 0.625 mg conjugated equine estrogens (CEE) and 2.5 mg medroxyprogesterone acetate (MPA), to be associated with decreased risks of… CONTINUE READING